Zymeworks (ZYME) Competitors $14.14 +0.13 (+0.93%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$14.29 +0.15 (+1.09%) As of 08:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZYME vs. ACAD, KRYS, CYTK, MENS, ADMA, PCVX, AAPG, PTCT, ACLX, and AKROShould you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Cytokinetics (CYTK), Jyong Biotech (MENS), ADMA Biologics (ADMA), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), PTC Therapeutics (PTCT), Arcellx (ACLX), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Zymeworks vs. Its Competitors ACADIA Pharmaceuticals Krystal Biotech Cytokinetics Jyong Biotech ADMA Biologics Vaxcyte Ascentage Pharma Group International PTC Therapeutics Arcellx Akero Therapeutics Zymeworks (NYSE:ZYME) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Is ZYME or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 21.80% compared to Zymeworks' net margin of -182.75%. ACADIA Pharmaceuticals' return on equity of 14.69% beat Zymeworks' return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-182.75% -23.00% -18.04% ACADIA Pharmaceuticals 21.80%14.69%9.41% Do analysts prefer ZYME or ACAD? Zymeworks presently has a consensus price target of $21.43, suggesting a potential upside of 51.55%. ACADIA Pharmaceuticals has a consensus price target of $28.88, suggesting a potential upside of 12.27%. Given Zymeworks' stronger consensus rating and higher probable upside, research analysts plainly believe Zymeworks is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90ACADIA Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.61 Does the media prefer ZYME or ACAD? In the previous week, ACADIA Pharmaceuticals had 10 more articles in the media than Zymeworks. MarketBeat recorded 22 mentions for ACADIA Pharmaceuticals and 12 mentions for Zymeworks. Zymeworks' average media sentiment score of 1.14 beat ACADIA Pharmaceuticals' score of 0.49 indicating that Zymeworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, ZYME or ACAD? Zymeworks has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Do institutionals & insiders hold more shares of ZYME or ACAD? 92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, ZYME or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$122.87M8.65-$118.67M-$0.97-14.58ACADIA Pharmaceuticals$957.80M4.53$226.45M$1.3319.34 SummaryACADIA Pharmaceuticals beats Zymeworks on 11 of the 16 factors compared between the two stocks. Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYME vs. The Competition Export to ExcelMetricZymeworksPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$1.05B$832.19M$5.77B$21.33BDividend YieldN/A4.84%6.66%3.49%P/E Ratio-9.431.1082.4329.16Price / Sales8.6526.60504.7347.12Price / CashN/A19.5625.7018.29Price / Book2.136.5710.935.30Net Income-$118.67M-$5.07M$3.28B$998.51M7 Day Performance-4.72%0.05%0.10%-0.63%1 Month Performance12.22%10.08%8.93%4.90%1 Year Performance22.00%25.34%51.89%13.95% Zymeworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYMEZymeworks2.3074 of 5 stars$14.14+0.9%$21.43+51.5%+22.7%$1.05B$122.87M-9.43460News CoveragePositive NewsGap DownACADACADIA Pharmaceuticals4.0457 of 5 stars$25.99-0.9%$28.88+11.1%+57.2%$4.38B$957.80M19.54510Analyst RevisionKRYSKrystal Biotech4.8418 of 5 stars$147.70-2.0%$210.38+42.4%-19.6%$4.27B$290.52M30.02210Positive NewsCYTKCytokinetics4.1757 of 5 stars$35.33-5.4%$71.58+102.6%-8.4%$4.23B$18.47M-6.93250Trending NewsAnalyst ForecastInsider TradeOptions VolumeMENSJyong BiotechN/A$54.81-1.3%N/AN/A$4.17BN/A0.0031News CoverageADMAADMA Biologics4.0239 of 5 stars$17.26-0.7%$27.67+60.3%+2.0%$4.12B$426.45M20.07530Positive NewsPCVXVaxcyte2.8171 of 5 stars$30.79+0.1%$136.50+343.3%-70.9%$4.00BN/A-7.49160News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$42.47+3.3%N/AN/A$3.95B$134.35M0.00600Positive NewsPTCTPTC Therapeutics3.9366 of 5 stars$49.33-0.9%$69.15+40.2%+66.3%$3.92B$806.78M7.081,410News CoverageAnalyst ForecastACLXArcellx2.2082 of 5 stars$69.39-1.2%$114.31+64.7%+7.7%$3.85B$107.94M-20.2980News CoveragePositive NewsAKROAkero Therapeutics3.9133 of 5 stars$46.73-0.4%$81.57+74.6%+75.5%$3.74BN/A-23.3730News CoveragePositive News Related Companies and Tools Related Companies ACAD Alternatives KRYS Alternatives CYTK Alternatives MENS Alternatives ADMA Alternatives PCVX Alternatives AAPG Alternatives PTCT Alternatives ACLX Alternatives AKRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ZYME) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
